Drug
Zoldonrasib clinical trials
Also written RMC-9805.
Keep track of what changes. Save the zoldonrasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Daraxonrasib (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Elironrasib (1) · Pembrolizumab (1) · Cisplatin (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses zoldonrasib is read from its arms, and is right about nine times in ten.
Testing it · 5
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as RMC-9805
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as zoldonrasib
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Zoldonrasib
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as RMC-9805
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingPhase 3Revolution Medicines, Inc.NCT07777822Written as zoldonrasib
Given in every arm · 3 — zoldonrasib is usual care beside what is tested
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06922591Written as RMC-9805
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as Zoldonrasib
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT06040541Written as RMC-9805
Codes
What other systems call zoldonrasib · ClinicalTrials.gg INT018469
- UNII (FDA) XJ52BWK3XEZOLDONRASIBOne source FDA
- NCI Thesaurus C201828ZoldonrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XJ52BWK3XE | ZOLDONRASIB | One source FDA |
| NCI Thesaurus | C201828 | Zoldonrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.